Beta Bionics CPO sells $58K in company stock

Beta Bionics’ chief product officer executed a Rule 10b5-1 planned sale of 2,650 shares while retaining 177,390 shares directly.

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) reported that Chief Product Officer Mike Mensinger sold 2,650 shares of common stock on September 16, 2026 at $22.00 per share in an open-market or private transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on September 8, 2025, and he continued to hold 177,390 shares of common stock directly after the transaction.

Insider Trade Summary 10b5-1

Net Seller: 2,650 shares

Net Sell 1 txn

Insider Mensinger Mike

Role Chief Product Officer

Sold 2,650 shs ($58K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	2,650	$22.00	$58K

Holdings After Transaction: Common Stock — 177,390 shares (Direct)

Footnotes (1)

1. F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.

Key Figures

Shares sold: 2,650 shares Sale price per share: $22.00 per share Approximate transaction value: $58,300 +2 more

5 metrics

Shares sold 2,650 shares Common stock sale reported for September 16, 2026

Sale price per share $22.00 per share Price for the 2,650 shares of common stock sold on September 16, 2026

Approximate transaction value $58,300 2,650 shares sold at $22.00 per share

Shares held after transaction 177,390 shares Direct holdings of common stock by Mike Mensinger after the reported sale

Rule 10b5-1 plan adoption date September 8, 2025 Trading plan under which the September 16, 2026 sale was executed

Key Terms

Rule 10b5-1 Plan, open market or private transaction

2 terms

Rule 10b5-1 Plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open market or private transaction market

"Described as a sale in an open market or private transaction."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BBNX disclose for Chief Product Officer Mike Mensinger?

BBNX disclosed that Chief Product Officer Mike Mensinger sold 2,650 shares of common stock on September 16, 2026 at $22.00 per share in an open-market or private transaction.

Was the September 16, 2026 BBNX insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the 2,650-share sale on September 16, 2026 was made pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.

How many BBNX shares does Mike Mensinger hold after this reported sale?

After the reported transaction, Mike Mensinger directly holds 177,390 shares of Beta Bionics, Inc. common stock.

What was the approximate value of the BBNX shares sold by the chief product officer?

The sale of 2,650 shares at $22.00 per share represents an approximate transaction value of $58,300, based on the reported per-share price and share count.

What role does the reporting person hold at Beta Bionics, Inc. (BBNX)?

The reporting person, Mike Mensinger, is identified in the filing as the Chief Product Officer of Beta Bionics, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:16 PM Accepted by SEC EDGAR 09/17/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mensinger Mike

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Product Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		S(1)		2,650	D	$22	177,390	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.

	/s/ Stephen Feider, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)